The Human and Financial Stakes
“This deal sets the stage for our portfolio to potentially transform the lives of hundreds of millions of people and delivers a strong outcome for our shareholders,” said Whit Bernard, co-founder and CEO of Metsera.
Behind the scenes, heavyweight advisers steered the negotiations. Citi advised Pfizer financially, while Metsera leaned on Goldman Sachs, Guggenheim, BofA Securities, and Allen & Co. Wachtell Lipton’s team was led by partners David K. Lam and Steven R. Green. On Metsera’s side, Paul Weiss fielded a high-powered team including Benjamin Goodchild, Andrew D. Krause, and Scott A. Barshay.
As the obesity treatment market swells into one of the pharmaceutical world’s most lucrative battlegrounds, Pfizer’s acquisition of Metsera could either be a brilliant comeback—or a multibillion-dollar gamble.
